Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
2seventy Bio Inc's Business Segments
2seventy Bio Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2025
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 23
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2025
- Reportable100%
Revenue by Reportable Segment - Q1 FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 23 | 100% |
Revenue by Product & Service Category - Q1 FY2025
- Service16.4%
- Royalty and other revenue0.1%
Revenue by Product & Service Category - Q1 FY2025
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Service | $ 4 | 16.4% |
| Royalty and other revenue | $ 0 | 0.1% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of 2seventy Bio Inc
2seventy Bio Inc is a biotechnology company that specializes in developing innovative solutions for the healthcare industry. The company was founded in , with a mission to revolutionize the field of bioengineering and provide cutting-edge products and services for the betterment of human health.
One of the key focuses of 2seventy Bio Inc is the development of advanced diagnostics and therapeutics. The company is dedicated to finding accurate and effective ways to diagnose diseases and develop targeted treatment options. They utilize state-of-the-art technologies and employ a team of skilled scientists, engineers, and medical professionals to accelerate the development of transformative solutions.
2seventy Bio Inc offers a wide range of diagnostic solutions that can detect various medical conditions with high precision and sensitivity. Their diagnostics include genetic tests, molecular tests, immunological tests, and imaging techniques. These tests can help in early disease detection, monitoring disease progression, and guiding treatment decisions. The company emphasizes the importance of personalized medicine and aims to deliver customized solutions tailored to individual patients' needs.
In addition to diagnostics, 2seventy Bio Inc is actively involved in the development of therapeutics. They focus on creating novel drugs and therapies that target specific diseases, including cancer, autoimmune disorders, and rare genetic conditions. The company combines their expertise in bioengineering, genomics, and drug discovery to identify and develop potent therapeutic molecules. They also invest in research collaborations with academic institutions and pharmaceutical companies to expand their therapeutic portfolio.
2seventy Bio Inc is committed to ensuring the safety and efficacy of their products. They adhere to stringent regulatory guidelines and quality control measures in all stages of product development and manufacturing. The company conducts rigorous clinical trials to validate the performance and safety of their diagnostics and therapeutics before they are made available to healthcare practitioners and patients.
Apart from diagnostics and therapeutics, 2seventy Bio Inc also engages in bioprocessing and bioinformatics. They offer services for large-scale production of bio-based products and provide bioinformatics solutions to process and analyze complex biological data. These services are designed to support academic researchers, pharmaceutical companies, and other organizations in their pursuit of scientific advancements.
To maintain a competitive edge in the market, 2seventy Bio Inc invests heavily in research and development. They continuously explore new technologies, collaborate with leading experts, and foster a culture of innovation within their organization. The company aims to stay at the forefront of bioengineering advancements and lead the way in developing breakthrough solutions for the healthcare industry.
Overall, 2seventy Bio Inc is a dynamic biotechnology company that strives to make a significant impact on human health. With their focus on diagnostics and therapeutics, commitment to quality and innovation, and collaborative approach, they are poised to shape the future of bioengineering and contribute to the advancement of medicine.
One of the key focuses of 2seventy Bio Inc is the development of advanced diagnostics and therapeutics. The company is dedicated to finding accurate and effective ways to diagnose diseases and develop targeted treatment options. They utilize state-of-the-art technologies and employ a team of skilled scientists, engineers, and medical professionals to accelerate the development of transformative solutions.
2seventy Bio Inc offers a wide range of diagnostic solutions that can detect various medical conditions with high precision and sensitivity. Their diagnostics include genetic tests, molecular tests, immunological tests, and imaging techniques. These tests can help in early disease detection, monitoring disease progression, and guiding treatment decisions. The company emphasizes the importance of personalized medicine and aims to deliver customized solutions tailored to individual patients' needs.
In addition to diagnostics, 2seventy Bio Inc is actively involved in the development of therapeutics. They focus on creating novel drugs and therapies that target specific diseases, including cancer, autoimmune disorders, and rare genetic conditions. The company combines their expertise in bioengineering, genomics, and drug discovery to identify and develop potent therapeutic molecules. They also invest in research collaborations with academic institutions and pharmaceutical companies to expand their therapeutic portfolio.
2seventy Bio Inc is committed to ensuring the safety and efficacy of their products. They adhere to stringent regulatory guidelines and quality control measures in all stages of product development and manufacturing. The company conducts rigorous clinical trials to validate the performance and safety of their diagnostics and therapeutics before they are made available to healthcare practitioners and patients.
Apart from diagnostics and therapeutics, 2seventy Bio Inc also engages in bioprocessing and bioinformatics. They offer services for large-scale production of bio-based products and provide bioinformatics solutions to process and analyze complex biological data. These services are designed to support academic researchers, pharmaceutical companies, and other organizations in their pursuit of scientific advancements.
To maintain a competitive edge in the market, 2seventy Bio Inc invests heavily in research and development. They continuously explore new technologies, collaborate with leading experts, and foster a culture of innovation within their organization. The company aims to stay at the forefront of bioengineering advancements and lead the way in developing breakthrough solutions for the healthcare industry.
Overall, 2seventy Bio Inc is a dynamic biotechnology company that strives to make a significant impact on human health. With their focus on diagnostics and therapeutics, commitment to quality and innovation, and collaborative approach, they are poised to shape the future of bioengineering and contribute to the advancement of medicine.
2seventy Bio Inc. is a biotechnology company focused on developing innovative therapies to transform the lives of patients with cancer and other serious diseases. The companys core competencies and offerings can be segmented into several key areas including cell therapy, gene therapy, and various product candidates targeting specific diseases.
Segments
1. Cell Therapy: 2seventy Bio is at the forefront of developing cell-based therapies, leveraging advanced techniques to engineer immune cells to target and kill cancer cells. This segment includes:
- CAR-T Therapies: Chimeric Antigen Receptor T-cell (CAR-T) therapy is a groundbreaking approach where patients T-cells are genetically modified to express receptors that specifically attack cancer cells. 2seventy Bio is focused on creating next-generation CAR-T products that may offer improved efficacy and safety profiles.
- TCR Therapy: T-cell receptor (TCR) therapy involves the engineering of T-cells to recognize specific tumor-associated antigens. This allows for a more precise attack on cancer cells that express those antigens.
2. Gene Therapy: The company is also engaged in exploring gene therapy as a means to deliver therapeutic genes directly into patients’ cells to treat genetic disorders or cancers. This segment includes:
- Adeno-associated Virus (AAV) Platforms: 2seventy Bio employs AAV vectors for gene delivery. These vectors are designed for specific targeting and expression within the cellular environment, enabling precision in addressing genetic abnormalities.
- Lentiviral Vectors: The company is also utilizing lentiviral technology to permit stable gene insertion into the genome of target cells, supporting sustained therapeutic effects.
3. Oncology Focus: A majority of 2seventy Bio’s research and product development is centered on oncology. The company is developing treatments for various cancers including:
- Hematologic Malignancies: Conditions such as leukemia and lymphoma are primary targets for the company’s therapies, addressing unmet medical needs in these areas.
- Solid Tumors: The development of therapies aimed at solid tumors represents a significant challenge due to the tumor microenvironment, and 2seventy Bio is actively working on products tailored for these indications.
Products and Services
1. Pipeline Products: 2seventy Bio has a robust pipeline consisting of several investigational therapies. Each product candidate is designed to address specific types of cancer and manifestations of disease. The company’s pipeline is often categorized by developmental stage, including:
- Preclinical Candidates: Early-stage research products that are undergoing initial evaluation for efficacy and safety.
- Clinical Trials: Several candidates enter clinical trials to assess their safety and effectiveness in human populations. This includes ongoing studies in various phases (Phase I, II, etc.) focused on generating data to support regulatory approvals.
- Commercial Products: Once products complete clinical trials successfully, they may transition into commercial manufacturing and distribution. While this segment may not currently include marketed products, it represents the goal of 2seventy Bios therapeutic development efforts.
2. Collaboration and Partnership Opportunities: The company actively seeks partnerships with academic institutions, industry stakeholders, and research organizations to enhance its research capabilities and product development. Collaborations may involve shared research projects, co-development agreements, and licensing arrangements that extend the reach and impact of its therapies.
3. Scientific and Patient Engagement Services: 2seventy Bio prioritizes engagement with the scientific community and patients, providing educational resources about its therapies and ongoing research initiatives. This includes:
- Clinical Trial Information: Offering insights and details about ongoing clinical trials to prospective participants, healthcare professionals, and researchers.
- Patient Resources: Developing support programs that empower patients and caregivers with information regarding disease management and therapeutic options.
Conclusion
2seventy Bio Inc. is positioned as a leader in the biotechnology space, harnessing the power of cell and gene therapies to create impactful treatments for cancer and other serious diseases. Its strategic focus on cutting-edge technology and innovative therapeutic approaches drives its research and development efforts across multiple segments aimed at addressing significant unmet medical needs.
Segments
1. Cell Therapy: 2seventy Bio is at the forefront of developing cell-based therapies, leveraging advanced techniques to engineer immune cells to target and kill cancer cells. This segment includes:
- CAR-T Therapies: Chimeric Antigen Receptor T-cell (CAR-T) therapy is a groundbreaking approach where patients T-cells are genetically modified to express receptors that specifically attack cancer cells. 2seventy Bio is focused on creating next-generation CAR-T products that may offer improved efficacy and safety profiles.
- TCR Therapy: T-cell receptor (TCR) therapy involves the engineering of T-cells to recognize specific tumor-associated antigens. This allows for a more precise attack on cancer cells that express those antigens.
2. Gene Therapy: The company is also engaged in exploring gene therapy as a means to deliver therapeutic genes directly into patients’ cells to treat genetic disorders or cancers. This segment includes:
- Adeno-associated Virus (AAV) Platforms: 2seventy Bio employs AAV vectors for gene delivery. These vectors are designed for specific targeting and expression within the cellular environment, enabling precision in addressing genetic abnormalities.
- Lentiviral Vectors: The company is also utilizing lentiviral technology to permit stable gene insertion into the genome of target cells, supporting sustained therapeutic effects.
3. Oncology Focus: A majority of 2seventy Bio’s research and product development is centered on oncology. The company is developing treatments for various cancers including:
- Hematologic Malignancies: Conditions such as leukemia and lymphoma are primary targets for the company’s therapies, addressing unmet medical needs in these areas.
- Solid Tumors: The development of therapies aimed at solid tumors represents a significant challenge due to the tumor microenvironment, and 2seventy Bio is actively working on products tailored for these indications.
Products and Services
1. Pipeline Products: 2seventy Bio has a robust pipeline consisting of several investigational therapies. Each product candidate is designed to address specific types of cancer and manifestations of disease. The company’s pipeline is often categorized by developmental stage, including:
- Preclinical Candidates: Early-stage research products that are undergoing initial evaluation for efficacy and safety.
- Clinical Trials: Several candidates enter clinical trials to assess their safety and effectiveness in human populations. This includes ongoing studies in various phases (Phase I, II, etc.) focused on generating data to support regulatory approvals.
- Commercial Products: Once products complete clinical trials successfully, they may transition into commercial manufacturing and distribution. While this segment may not currently include marketed products, it represents the goal of 2seventy Bios therapeutic development efforts.
2. Collaboration and Partnership Opportunities: The company actively seeks partnerships with academic institutions, industry stakeholders, and research organizations to enhance its research capabilities and product development. Collaborations may involve shared research projects, co-development agreements, and licensing arrangements that extend the reach and impact of its therapies.
3. Scientific and Patient Engagement Services: 2seventy Bio prioritizes engagement with the scientific community and patients, providing educational resources about its therapies and ongoing research initiatives. This includes:
- Clinical Trial Information: Offering insights and details about ongoing clinical trials to prospective participants, healthcare professionals, and researchers.
- Patient Resources: Developing support programs that empower patients and caregivers with information regarding disease management and therapeutic options.
Conclusion
2seventy Bio Inc. is positioned as a leader in the biotechnology space, harnessing the power of cell and gene therapies to create impactful treatments for cancer and other serious diseases. Its strategic focus on cutting-edge technology and innovative therapeutic approaches drives its research and development efforts across multiple segments aimed at addressing significant unmet medical needs.